Market Overview:
Tissue plasminogen activator (tPA) is a thrombolytic agent that helps in dissolving blood clots and restoring blood flow. It is commonly used for treating pulmonary embolism, deep vein thrombosis, and arterial thrombosis.

Market Dynamics:
Growing burden of thrombotic disorders- Rapid urbanization, sedentary lifestyles, and growing geriatric population have led to a significant rise in the cases of deep vein thrombosis, pulmonary embolism, and arterial thrombosis globally. As per estimates by World Health Organization, around 24 million people worldwide suffer from myocardial infarction every year. Tissue plasminogen activator is the first line of treatment for many thrombotic conditions, which is expected to drive its demand over the forecast period.
Rising awareness about thrombolysis treatment- Continuous educational programs by government and non-profit organizations have raised awareness about thrombolysis treatment using tPA among public as well as healthcare professionals. This has resulted in early diagnosis and treatment seekers, thereby supporting revenue growth of the tPA market.

Market key trends:
The Tissue Plasminogen Activator Market Size has been witnessing increased research and development activities from key players. The companies are focusing on developing novel recombinant tissue plasminogen activator drugs with improved efficacy and reduced side effects. Furthermore, the rising burden of strokes worldwide has also boosted clinical research on tPA to expand therapy time window.

SWOT Analysis:
Strength: Presence of large number of companies with strong product portfolio.
Weakness: Short therapeutic window of currently approved tPA drugs.
Opportunity: Growth opportunities in expanding approved indications and developing new formulations.
Threats: Stiff competition among existing players and entry of new local players.

Key Takeaways:
The global tissue plasminogen activator market is expected to witness high growth, exhibiting CAGR of 5.2% over the forecast period, due to increasing prevalence of strokes. The United States dominates the global tissue plasminogen activator market owing to high treatment cost and accessibility to advanced healthcare facilities. The market in the Asia Pacific region is expected to grow at a fast pace due to growing healthcare infrastructure and rapidly rising geriatric population.

Regional analysis:
The United States is expected to dominate the global market due to high treatment cost and presence of major players. The Asia Pacific region is projected to exhibit exponential growth during the forecast period owing to improving healthcare infrastructure and rising medical tourism across developing nations like India and China.

Key players:
Key players operating in the tissue plasminogen activator market are F. Hoffmann-La Roche AG, Boehringer Ingelheim GmbH, CHIESI Farmaceutici S.p.A., Gennova Biopharmaceuticals Ltd, Abbott Laboratories, and Reliance Life Sciences.

Read More:

http://marketerefforts.weebly.com/home/the-tissue-plasminogen-activator-market-growth